Comment
doi: 10.1001/jamaoncol.2023.0254.
Prostate-Specific Antigen Screening Should Not Be Covered by Publicly Funded Health Insurance
Affiliations
- PMID: 37052905
- DOI: 10.1001/jamaoncol.2023.0254
Item in Clipboard
Comment
Prostate-Specific Antigen Screening Should Not Be Covered by Publicly Funded Health Insurance
JAMA Oncol.
.
No abstract available
Comment in
-
Prostate-Specific Antigen Screening Should Not Be Covered by Publicly Funded Health Insurance-Reply.JAMA Oncol. 2023 Jun 1;9(6):868-869. doi: 10.1001/jamaoncol.2023.0257. JAMA Oncol. 2023. PMID: 37052900 No abstract available.
Comment on
-
Cost-effectiveness of Prostate Cancer Screening Using Magnetic Resonance Imaging or Standard Biopsy Based on the STHLM3-MRI Study.JAMA Oncol. 2022 Nov 10;9(1):88-94. doi: 10.1001/jamaoncol.2022.5252. Online ahead of print. JAMA Oncol. 2022. PMID: 36355382 Free PMC article.
Similar articles
-
Prostate-Specific Antigen Screening Should Not Be Covered by Publicly Funded Health Insurance-Reply.JAMA Oncol. 2023 Jun 1;9(6):868-869. doi: 10.1001/jamaoncol.2023.0257. JAMA Oncol. 2023. PMID: 37052900 No abstract available.
-
Interrelationship Between Health Insurance Status and Prostate Cancer Grade Can Have Critical Impact on Prostate Cancer Disease Control: A Retrospective Cohort Study.Cancer Control. 2019 Jan-Dec;26(1):1073274819837184. doi: 10.1177/1073274819837184. Cancer Control. 2019. PMID: 30935222 Free PMC article.
-
Sources of health insurance and characteristics of the uninsured. Analysis of the March 1992 Current Population Survey.EBRI Issue Brief. 1993 Jan;(133):1-70. EBRI Issue Brief. 1993. PMID: 10129611
-
StatBite: Percentage screened for cancer by insurance status.J Natl Cancer Inst. 2008 Jun 4;100(11):772. doi: 10.1093/jnci/djn173. Epub 2008 May 27. J Natl Cancer Inst. 2008. PMID: 18505962 No abstract available.
-
Simple truths about America's uninsured.Am J Nurs. 2007 Jan;107(1):40-3, 46-7. doi: 10.1097/00000446-200701000-00019. Am J Nurs. 2007. PMID: 17202873 Review.
Cited by
-
Cost-effectiveness analysis of prostate cancer screening and MRI.World J Urol. 2024 Apr 5;42(1):212. doi: 10.1007/s00345-024-04943-0. World J Urol. 2024. PMID: 38578452 No abstract available.
-
Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening.World J Urol. 2024 Mar 16;42(1):167. doi: 10.1007/s00345-024-04905-6. World J Urol. 2024. PMID: 38492072 No abstract available.
-
Cost-utility analysis of MR imaging-guided transurethral ultrasound ablation for the treatment of low- to intermediate-risk localised prostate cancer.BMJ Open. 2025 Jan 11;15(1):e088495. doi: 10.1136/bmjopen-2024-088495. BMJ Open. 2025. PMID: 39800402 Free PMC article.
-
Prebiopsy Risk Calculators, Such as MRI and Prostate Cancer Screening, Are Early-phase Clinical Trials.Radiology. 2023 Nov;309(2):e231177. doi: 10.1148/radiol.231177. Radiology. 2023. PMID: 37962502 Free PMC article. No abstract available.
-
Guidelines by Urologists and Public Health Professionals: Different Perspectives on Prostate Specific Antigen Screening.J Cancer Educ. 2023 Aug;38(4):1109-1110. doi: 10.1007/s13187-023-02331-7. Epub 2023 Jun 17. J Cancer Educ. 2023. PMID: 37330457 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
